Dailymirror.news,March 1st,2025: Zydus, a global pharmaceutical leader known for its discovery-based innovations, is set to launch India’s first flu protection for the 2025 Southern Hemisphere season.

The company’s Quadrivalent Inactivated Influenza vaccine, VaxiFlu-4, has been formulated as per the WHO-recommended composition for quadrivalent influenza vaccines, offering protection against:

  • A/Victoria/4897/2022 (H1N1)pdm09-like virus
  • A/Croatia/10136RV/2023 (H3N2)-like virus
  • B/Austria/1359417/2021 (B/Victoria lineage)-like virus
  • B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

Read this also...A Grand Celebration of Telugu Cinema at Red Lorry Film Festival: Parallel Verse in Hyderabad

Read this also...Mindspace Eco Run 2025: Fitness for You, Sustainability for All..

By covering both Influenza A and Influenza B strains, quadrivalent vaccines provide broader protection, reducing the risk of vaccine mismatch. The vaccine has been cleared by the Central Drug Laboratory (CDL) in India.

VaxiFlu-4 will be marketed under Zydus Vaxxicare, a division focused on preventive healthcare. It was developed at the Vaccine Technology Centre (VTC) in Ahmedabad, which specializes in researching, developing, and manufacturing safe and effective vaccines.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the role of preventive healthcare, stating,“Vaccines play a crucial role in improving public health globally. In India, the need for affordable, high-quality vaccines is greater than ever. With VaxiFlu-4, we are strengthening annual immunization efforts and helping prevent flu outbreaks.”

ఇది కూడా చదవండి..యాక్సిస్ నిఫ్టీ AAA బాండ్ ఫండ్స్ – మార్చ్ 2028 ఆవిష్కరణ..

Read this also..Axis Mutual Fund Launches AXIS Nifty AAA Bond Financial Services – Mar 2028 Index Fund..

Influenza continues to pose a serious public health challenge, with annual outbreaks leading to severe complications, hospitalizations, and fatalities. The flu virus spreads through airborne respiratory droplets from coughing and sneezing or through direct contact with infected surfaces or individuals.

The most vulnerable populations include:

  • Children under five
  • The elderly
  • People with chronic illnesses or weakened immune systems

According to the World Health Organization (WHO), seasonal influenza leads to 290,000-650,000 deaths worldwide every year. Annual flu vaccination remains the best preventive measure against influenza and its complications.

With VaxiFlu-4, Zydus Lifesciences aims to reinforce public health efforts by providing a scientifically advanced, WHO-compliant, and easily accessible flu vaccine for India.